A global, randomized, double-blind, multicenter Phase III study of Rilvegostomig or Pembrolizumab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (D702BC00001).
Principal Investigator
Dott.ssa Vanesa Gregorc
Contact Information for Access
Phase
FASE III
Status
ATTIVO
Objective of the study
To evaluate whether rilvegostomig monotherapy improves clinical efficacy compared with pembrolizumab monotherapy as a first-line treatment in patients with metastatic NSCLC with high PD-L1 expression.
ClinicalTrials.gov ID NCT06868277
Sponsor: AstraZeneca
Pathologies
Lung Cancer
Medication
Rilvegostomig
, Pembrolizumab
Who is eligible to participate in the study?
Patients who are 18 years of age or older, meet the study’s eligibility criteria, and have not previously been treated for NSCLC may participate in this study.
View the full study Back to search page